Segall Bryant & Hamill’s Adaptive Biotechnologies ADPT Stock Holding History

Segall Bryant & Hamill’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-152,014	Closed	-$1.23M	–	723
2022 Q2	$1.23M	Buy	152,014 +44,973	+42%	+$395K	0.01%	476
2022 Q1	$1.49M	Buy	107,041 +267	+0.3%	+$4.2K	0.01%	475
2021 Q4	$3M	Buy	106,774 +4,970	+5%	+$152K	0.03%	379
2021 Q3	$3.46M	Buy	101,804 +2,708	+3%	+$97.9K	0.03%	395
2021 Q2	$4.05M	Buy	99,096 +6,002	+6%	+$233K	0.04%	364
2021 Q1	$3.75M	Sell	93,094 -1,586	-2%	-$85.8K	0.04%	387
2020 Q4	$5.6M	Sell	94,680 -1,782	-2%	-$91.9K	0.06%	275
2020 Q3	$4.69M	Buy	96,462 +70,037	+265%	+$2.94M	0.06%	269
2020 Q2	$1.28M	Buy	26,425 +12,475	+89%	+$455K	0.02%	396
2020 Q1	$388K	Buy	+13,950	New	+$389K	0.01%	630

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Segall Bryant & Hamill's ADPT Position: Q3 2022 in Review

Segall Bryant & Hamill sold out of Adaptive Biotechnologies (ADPT) in Q3 2022, closing a stake of 152,014 shares — an estimated $1.23M sold.

Segall Bryant & Hamill first reported a position in ADPT in Q1 2020 and held it in 10 quarters. The position peaked at $5.6M in Q4 2020. 226 funds tracked by Wall St. Rank hold ADPT as of Q3 2022.

Segall Bryant & Hamill reported no remaining Adaptive Biotechnologies position as of Q3 2022 after selling out during the quarter.
Segall Bryant & Hamill sold 152,014 Adaptive Biotechnologies shares in Q3 2022, an estimated $1.23M.
Segall Bryant & Hamill first reported a position in Adaptive Biotechnologies in Q1 2020 and held it in 10 quarters.
Segall Bryant & Hamill's Adaptive Biotechnologies position peaked at $5.6M in Q4 2020.
226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2022.

Based on Segall Bryant & Hamill's 13F filing for Q3 2022, filed 14 Nov 2022.